↓ Skip to main content

Standardization of double blind placebo controlled food challenge with soy within a multicentre trial

Overview of attention for article published in Clinical and Translational Allergy, November 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)

Mentioned by

twitter
7 X users
facebook
1 Facebook page

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
30 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Standardization of double blind placebo controlled food challenge with soy within a multicentre trial
Published in
Clinical and Translational Allergy, November 2016
DOI 10.1186/s13601-016-0129-4
Pubmed ID
Authors

R. Treudler, A. Franke, A. Schmiedeknecht, B. K. Ballmer-Weber, M. Worm, T. Werfel, U. Jappe, T. Biedermann, J. Schmitt, R. Brehler, A. Kleinheinz, J. Kleine-Tebbe, H. Brüning, F. Ruëff, J. Ring, J. Saloga, K. Schäkel, T. Holzhauser, St. Vieths, J. C. Simon

Abstract

Multicentre trials investigating food allergies by double blind placebo controlled food challenges (DBPCFC) need standardized procedures, challenge meals and evaluation criteria. We aimed at developing a standardized approach for identifying patients with birch related soy allergy by means of DBPCFC to soy, including determination of threshold levels, in a multicentre setting. Microbiologically stable soy challenge meals were composed of protein isolate with consistent Gly m 4 levels. Patients sensitized to main birch allergen Bet v 1 and concomitant sensitization to its soy homologue Gly m 4 underwent DBPCFC. Outcome was defined according to presence and/or absence of ten objective signs and intensity of eight subjective symptoms as measured by visual analogue scale (VAS). 138 adult subjects (63.8% female, mean age 38 years) underwent DBPCFC. Challenge meals and defined evaluation criteria showed good applicability in all centres involved. 45.7% presented with objective signs and 65.2% with subjective symptoms at soy challenge. Placebo challenge meals elicited non-cardiovascular objective signs in 11.6%. In 82 (59.4%) subjects DBPCFC was judged as positive. 70.7% of DPBCFC+ showed objective signs and 85.4% subjective symptoms at soy challenge. Subjective symptoms to soy challenge meal in DBPCFC+ subjects started at significantly lower dose levels than objective signs (p < 0.001). Median cumulative eliciting doses for first objective signs in DBPCFC+ subjects were 4.7 g [0.7-24.7] and 0.7 g [0.2-4.7] total soy protein for first subjective symptoms (p = 0.01). We present the hitherto largest group of adults with Bet v 1 and Gly m 4 sensitization being investigated by DBPCFC. In this type of food allergy evaluation of DBPCFC outcome should not only include monitoring of objective signs but also scoring of subjective symptoms. Our data may contribute to standardize DBPCFC in pollen-related food allergy in multicentre settings. EudraCT: 2009-011737-27.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 30 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 4 13%
Student > Ph. D. Student 3 10%
Professor 2 7%
Researcher 2 7%
Student > Bachelor 1 3%
Other 5 17%
Unknown 13 43%
Readers by discipline Count As %
Agricultural and Biological Sciences 4 13%
Medicine and Dentistry 4 13%
Nursing and Health Professions 4 13%
Biochemistry, Genetics and Molecular Biology 2 7%
Immunology and Microbiology 2 7%
Other 1 3%
Unknown 13 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 February 2017.
All research outputs
#6,397,046
of 22,899,952 outputs
Outputs from Clinical and Translational Allergy
#349
of 667 outputs
Outputs of similar age
#98,127
of 312,379 outputs
Outputs of similar age from Clinical and Translational Allergy
#8
of 10 outputs
Altmetric has tracked 22,899,952 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 667 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,379 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.